Phase I pharmacokinetic, and pharmacodynamic trial of the novel oral notch inhibitor MK-0752 in patients with advanced breast cancer and other solid tumors.

被引：0
|
作者：
Krop, I. E.
Kosh, M.
Fearen, I
Savoie, J.
Dallob, A.
Stone, J.
Winer, E.
Freedman, S. J.
LoRusso, P.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Merck Res Labs, N Wales, PA USA
[3] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S287 / S287
页数：1
相关论文
共 50 条
  • [11] A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours
    I Brana
    R Berger
    T Golan
    P Haluska
    J Edenfield
    J Fiorica
    J Stephenson
    L P Martin
    S Westin
    P Hanjani
    M B Jones
    K Almhanna
    R M Wenham
    D M Sullivan
    W S Dalton
    A Gunchenko
    J D Cheng
    L L Siu
    J E Gray
    British Journal of Cancer, 2014, 111 : 1932 - 1944
  • [12] Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors
    O'Donnell, Anne
    Faivre, Sandrine
    Burris, Howard A., III
    Rea, Daniel
    Papadimitrakopoulou, Vassiliki
    Shand, Nicholas
    Lane, Heidi A.
    Hazell, Katharine
    Zoellner, Ulrike
    Kovarik, John M.
    Brock, Cathryn
    Jones, Suzanne
    Raymond, Eric
    Judson, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1588 - 1595
  • [13] A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors.
    Horn, Leora
    Infante, Jeffrey R.
    Blumenschein, George R.
    Wakelee, Heather A.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Liang, Chris
    Harrow, Kimberly
    Gibbons, Jay
    Lovly, Christine Marie
    Pao, William
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [14] A phase I trial of the novel oral taxane BMS-275183 in patients with advanced solid tumors.
    Broker, LE
    De Vos, FY
    Gall, H
    Gietema, JA
    Voi, M
    Cohen, MB
    De Vries, EG
    Giaccone, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 134S - 134S
  • [15] Phase I clinical, pharmacokinetic, and pharmacodynamic study of CG200745, a histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors.
    Kim, Kyu-Pyo
    Hong, Yong Sang
    Ahn, Jin-Hee
    Lee, Jae-Lyun
    Bae, Kyun-Seop
    Kim, Tae Won
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [16] A phase I pharmacodynamic and pharmacokinetic study of a Ras inhibitor, PRLX 93936, in patients with advanced solid tumors
    Ramanathan, R. K.
    Rosen, P. J.
    Wagner, A. J.
    Sahasrabudhe, S.
    Weiss, G. J.
    Lee, P.
    Fuerst, M.
    Robbins, P.
    Litka, P.
    Von Hoff, D. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [17] Phase I and pharimacokinetic trial of a novel inhibitor of NAD biosynthesis in patients with solid tumors.
    Holen, KD
    Bolling, C
    Saltz, LB
    Graefe, T
    Ty, V
    Sogo, N
    Starkmann, H
    Burk, KH
    Hollywood, E
    Hanauske, AR
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6158S - 6158S
  • [18] Phase I and pharmacokinetic (PK)/pharmacodynamic (PD) study of LY2334737, an oral gemcitabine prodrug, in patients (pts) with advanced solid tumors.
    Faivre, Sandrine J.
    Olszanski, Anthony J.
    Weigang-Koehler, Karin
    Riess, Hanno
    Peng, Guangbin
    Callies, Sophie
    Benhadji, Karim Adnane
    Raymond, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [19] First-in-human, Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat, an Oral Histone Deacetylase Inhibitor, in Patients with Advanced Solid Tumors
    Brunetto, Andre T.
    Ang, Joo Ern
    Lal, Rohit
    Olmos, David
    Molife, L. Rhoda
    Kristeleit, Rebecca
    Parker, Ann
    Casamayor, Isabel
    Olaleye, Muyibat
    Mais, Anna
    Hauns, Bernhard
    Strobel, Vera
    Hentsch, Bernd
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5494 - 5504
  • [20] Phase I pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent OX14503 in patients with advanced solid tumors.
    Zweifel, M.
    Patterson, D. M.
    Padhani, A. R.
    Middleton, M. R.
    Price, P.
    Stratford, M. R.
    Ross, P.
    Halford, S.
    Goldberg, Z.
    Rustin, G. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345